HDMA Honors Lupin Ltd. with DIANA Award for Best Overall Generic Manufacturer
Published: Jun 13, 2011
MUMBAI, India, June 13, 2011 /PRNewswire/ -- Pharma Major Lupin Limited announced today that its U.S. subsidiary, Lupin Pharmaceutical Inc. was presented with the 2011 DIANA Award by the Healthcare Distribution Management Association (HDMA) for the Best Overall Generic Product Manufacturer among those companies with sales of up to $100 million in the Healthcare Distributor market.
The DIANA award winners are selected by HDMA Distributor members to recognize companies that continually foster strong trading partner relationships with the Association's primary distributor members by creating exceptional business practices that advance trade relations and benefit the entire US healthcare supply chain.
Commenting on the award, Paul McGarty, President of Lupin Pharmaceuticals Inc. said, "We are very pleased and honored with the recognition that Lupin received from the HDMA." Mr. McGarty added, "This is very exciting when we consider that Lupin launched its Generics Rx division in December 2005 and this award is a reflection of our unwavering commitment to excellence and collaborative relationships with our trading partners."
About Lupin Limited
Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs. The Company today has significant presence in Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs in addition to holding global leadership positions in the Anti-TB and Cephalosporins space.
Today, Lupin is the 5th largest and the fastest growing Top 5 generics player in the U.S. (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical players in India, Japan and South Africa. (IMS)
For the financial year ended March 2011, Lupin's Consolidated Sales and Profit after Tax were Rs. 57,068 million and Rs. 8,626 million respectively. Please visit http://www.lupinworld.com for more information about Lupin Ltd.
Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Ltd. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com.
For further information please contact:
Ph: +91 98 20 338 555
Text 100 Public Relations
Ph: +91 98 20 11 2481
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.
(BSE : 500257)
(BLOOMBERG: LPC IN)
SOURCE Lupin Pharmaceuticals, Inc.